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CK2 = casein kinase 2; CypB = cyclophilin B; EGF = = epidermal growth factor; EGFr = epidermal growth factor receptor; ER = endoplasmic
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hormone receptor; IFN = interferon; IL = interleukin; MHC = major histocompatibility complex; PIAS3 = peptide inhibitor of activated Stat3; PRL =
prolactin; PRLr = prolactin receptor; PPI = peptidyl prolyl isomerase.
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Introduction
Peptide hormones and their cognate receptors are
required for the development and differentiation of the
mammary gland. The traditional paradigm of peptide
hormone/receptor action in mammary tissues is best
summarized as one of ‘action-at-a-distance’. In short, a
temporal and spatial activation of receptor-associated
transduction/transcription factors is thought to mediate a
specific signal triggered by ligand binding. These net-
works undoubtedly induce the necessary post-transla-
tional modifications (phosphorylation/dephosphorylation,
prolyl isomerization, proteolytic cleavage, etc.) required for
transcription factor/co-activator function. On careful exam-
ination of the signaling networks emerging from function-
ally disparate peptide hormone receptors, however, a
molecular basis for specificity remains unclear, as the
transduction cascades utilized by these receptors are
widely shared.
A potential solution to the conundrum of polypeptide
hormone specificity has recently emerged in a series of
articles detailing the intranuclear translocation and action
of peptide ligands and their receptors, or fragments
thereof. As contrasted later, striking parallels in the
intranuclear actions of peptide hormone/receptors exist
with steroid and Notch receptor complexes. These find-
ings taken together lead to the novel hypothesis that
peptide hormone specificity is generated by the conjoint
activation of receptor-associated signaling networks (i.e.
‘nongenomic action’) and by the direct intranuclear function
of ligand and/or receptor complexes (i.e. ‘genomic action’).
Translocation and function of polypeptide
receptors within the nucleus
Several transmembrane polypeptide receptors have been
reported within the nucleus, including epidermal growth
factor receptor (EGFr) [1], erbB-3 [2], erbB-4 [3], fibroblast
growth factor receptor (FGFr) [4,5], nerve growth factor
receptor [6], IL-5 [7], prolactin receptor (PRLr) [8], and
growth hormone receptor (GHr)/growth hormone receptor
binding protein [9,10]. Aside from delineating the nuclear
localization of these peptides, recent studies have begun to
elucidate their potential intranuclear functions and mecha-
nisms of nuclear internalization (also referred to as ‘retrotrans-
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Abstract
The specific effects triggered by polypeptide hormone/growth factor stimulation of mammary cells
were considered mediated solely by receptor-associated signaling networks. A compelling body of
new data, however, clearly indicates that polypeptide ligands and/or their receptors are transported
into the nucleus, where they function directly to regulate the expression of specific transcription factors
and gene loci. The intranuclear function of these complexes may contribute to the explicit functions
associated with a given ligand, and may serve as new targets for pharmacologic intervention.
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port’). The present review will focus on those receptors with
acknowledged function within the mammary gland.
Epidermal growth factor receptor
While immunohistochemical and biochemical studies have
localized the EGFr within the nucleus, the potential func-
tion of this receptor at this site has only been recently
elaborated [1]. Through the use of cross-linked 125I-epi-
dermal growth factor (EGF), Kwong and colleagues
revealed that phosphorylated, full-length EGFr is rapidly
transported into the nucleus within 1 min of ligand stimula-
tion. They also showed that the C-terminal (intracytoplas-
mic) domain of the EGFr potently activated the expression
of a luciferase reporter construct when fused to a GAL
DNA binding domain. Using the approach of cyclic amplifi-
cation and selection of targets (‘CASTing’), Kwong and
colleagues demonstrated that the EGFr preferentially
bound to an AT-rich sequence. Stimulation of cells trans-
fected with a luciferase reporter construct containing this
AT-rich sequence resulted in EGF-induced expression of
the reporter. Furthermore, when a similar sequence was
identified in the cyclin D1 (an EGF-inducible gene) pro-
moter region and subsequently mutated in a reporter con-
struct, EGF-induced expression was lost. Additional in
vivo  confirmation of a physical association of the EGFr
with the endogenous promoter region of cyclin D1 was
demonstrated by chromatin immunoprecipitation analysis.
These findings taken together suggest that the nuclear
retrotransport and promoter binding of the EGFr following
ligand stimulation may contribute to the expression of spe-
cific EGF-induced genes. While this study represents a
groundbreaking analysis of intranuclear EGFr function [1],
several points remain to be addressed: how does the cell
surface EGFr extricate itself from the plasma membrane?
How does the EGFr cross the nuclear membrane? How
does the intranuclear EGFr modulate endogenous gene
expression from a mechanistic perspective? What gene
loci are transactivated by the intranuclear EGFr? Indeed,
the lack of a defined mechanism for EGFr extrication from
the cell membrane and retrotransport to the nucleus has
been challenged [11]. The facts remain, however, that
multiple independent studies have now demonstrated
EGFr within the nucleus [1,12]. The inability of some
groups to reproduce these findings [11] may be related to
the difficulty of some anti-EGFr antibodies to recognize
the EGF in certain intracellular environments.
erbB-3
A recent study [2] has elegantly demonstrated, by confo-
cal immunomicroscopy, immunogold electron microscopy,
and biochemistry, the existence of full-length erbB-3 within
the nucleus of several cultured malignant human breast
cancer lines. Unlike the functional studies already detailed
for the EGFr, Offterdinger and colleagues [2] examined
the basis for the nuclear transport of erbB-3.
Structure/function mutagenesis revealed a sequence in
erbB-3 (termed NLS-2; RRRRHSP) that functioned as a
nuclear internalization signal. As such, their study is note-
worthy for its direct demonstration of this motif; however,
the study needs independent confirmation and does not
address any potential intranuclear function of erbB-3, nor
has intranuclear erbB-3 been demonstrated in malignant
or normal tissues. In addition, the mechanisms through
which erbB-3 can remove itself from the cell membrane
prior to nuclear translocation remain unresolved.
erbB-4
The presence of a soluble fragment of erbB-4 within the
nucleus has been recently reported [3], following reports
of the erbB-4 receptor within the nuclei of primary human
breast cancers [13]. This fragment spanning the intracyto-
plasmic domain of this receptor appears to be the result of
a sequential cleavage of erbB-4; first by an unidentified
metalloprotease (resulting in cleavage of a soluble extra-
cellular domain and a membrane-bound intracytoplasmic
domain), followed by cleavage of the intracytoplasmic
domain proper (into a cytoplasmic-soluble form), by a
γ-secretase-like activity. This was shown through the use of
pharmacologic inhibitors or dominant-negative precursors
of γ-secretase that effectively blocked the formation of the
soluble erbB-4 fragment. Use of immunofluorescence-
based studies revealed that this fragment was capable of
nuclear retrotransport, and that the motif mediating this
event was present in the C-terminus of the intracytoplas-
mic domain. Fusion of the erbB-4 intracytoplasmic domain
to the GAL4 DNA binding domain revealed a modest
transactivation of a GAL4 reporter construct, suggesting
that the erbB-4 fragment may be capable of modulating
endogenous gene expression.
The study by Ni and colleagues [3] is remarkable because
it demonstrated parallels between erbB-4 and Notch sig-
naling. However, whether the erbB-4 fragment is associ-
ated with active chromatin and which gene loci this
fragment activates remain to be determined. In addition,
formal biochemical proof of the existence of this fragment
within the nucleus remains to be demonstrated, as well as
the precise motifs involved in the nuclear retrotransport
and transactivation.
Fibroblast growth factor receptor
Stimulation of FGFr-expressing cells with fibroblast
growth factor (FGF) 2 results in the nuclear translocation
of the complex, despite the absence of a classic nuclear
localization signal sequence in either the receptor or the
ligand [14]. Continued work on this system has revealed
that the nuclear transport of full-length FGFr is dependent
upon importin β [5], as a FGFr/importin β complex is gen-
erated following ligand stimulation and as the immunode-
pletion of importin β blocks FGFr uptake in an isolated
nuclear transport system. Targeting of FGFr directly into the183
nucleus (by replacement of its endoplasmic reticulum [ER]
leader signal with a nuclear localization signal sequence
from SV40 T antigen) resulted in enhanced c-Jun and cyclin
D1 expression.
As with the members of the EGFr/erbB family, the mecha-
nisms of transport of the FGFr from the cell membrane
remain to be determined. In addition, the motifs required
for receptor-induced gene expression have not been iden-
tified, and the physical association of the FGFr with the
transcriptional apparatus on the endogenous c-Jun and
cyclin D1 loci requires demonstration.
Growth hormone receptor
The presence of both growth hormone and the GHr within
the nucleus has been previously demonstrated [15].
Recent data from Lobie and colleagues have suggested
that the extracellular domain of the GHr, also known as the
growth hormone binding protein (GHBP), exists and func-
tions within the nucleus in a manner independent of the
ligand [9]. These studies have demonstrated that a
modest potentiation of the expression of a Spi2.1 reporter
construct occurred upon transfection of the GHBP. The
potentiation of the expression of this reporter construct
was increased if a nuclear localization signal was added to
the GHBP via a recombinant technique [9]. These studies
suggest that the extracellular domain of the GHBP may
stimulate Spi2.1 transcription. These studies stand in con-
trast to other reports that suggest the GHBP acts in a
dominant negative manner [16]. In addition, the manner of
nuclear transport of the GHBP from either the ER or extra-
cellular space, the effect of GHBP on endogenous gene
expression, the gene loci activated by the GHBP, and the
mechanisms utilized during transcriptional activation
remain to be determined.
Prolactin receptor
The nuclear retrotransport of the PRLr has been noted
[8,17] and associated with the activation of nuclear
protein kinase C. Little else is know of the mechanisms of
its nuclear internalization or intranuclear function. Indeed,
whether the intranuclear PRLr represents a full-length
receptor or a fragment thereof has been debated.
Translocation and function of polypeptide
ligands within the nucleus
The nuclear retrotransport of numerous polypeptide
ligands, including prolactin (PRL) [18–21], growth
hormone [15], EGF [22], IFN-γ [23], nerve growth factor
[6,22], platelet-derived growth factor [22], FGF [24–26],
IL-5 [7], and insulin [27–29], has been reported within the
nucleus following their addition into the extracellular
medium. While the intranuclear transport and action of
many of these ligands are not known, a considerable
understanding of such mechanisms for FGF and PRL has
been newly forthcoming, and is now detailed.
Fibroblast growth factor
A growing body of evidence has indicated a function for
FGF internalized within the cytoplasm, and possibly within
the nucleus. Precedent reports from Olsnes and col-
leagues have demonstrated that FGF is retrotransported
into the cytoplasm and nucleus [26]. This transport
required several hours and was dependent on the cyto-
plasmic domain of the FGFr, but not on its kinase activity
[25]. Stimulation of NIH3T3 cells by the external applica-
tion of a mutant FGF ligand containing a CAAX motif
resulted in the demonstrable intracellular and intranuclear
farnesylation of this mutant after several hours [30],
revealing that the intracellular FGF was capable of cross-
ing cellular membranes. Following receptor-mediated
endocytosis, FGF could be found in the Golgi/ER. Trans-
port from this vesicular compartment required the pres-
ence of an active proton pump; when blocked with the
specific inhibitor bafilomycin A1, entry into the cytoplasm
was blocked [31]. In the absence of FGFr, a fusion
protein of FGF and diphtheria toxin was capable of stimu-
lating the proliferation of NIH3T3 cells expressing diph-
theria toxin receptor [26]. These data suggest that the
primary function of the FGFr, with respect to FGF-
induced mitogenesis, was for the endocytosis of FGF.
Phosphorylation of FGF appeared to contribute to its
mitogenicity, as a specific mutation (K132E) to FGF
resulted in a ligand demonstrating comparable levels of
receptor binding and activation, but demonstrating
decreased phosphorylation and ligand-induced prolifera-
tion [32].
What is the function of intracellular FGF? Several proteins
have been found to interact with FGF intracellularly,
including FGF intracellular binding protein, mortalin,
synaptotagmin, and S100A13. A recent study has also
demonstrated an interaction between FGF and casein
kinase 2 (CK2) [33]. The interaction between these pro-
teins, as determined by surface plasmon resonance, was
of moderate affinity (in the order of 1 µM). Despite this, in
vitro FGF was phosphorylated by CK2 and, in turn, the
presence of FGF stimulated the autophosphorylation of
CK2 [33]. CK2, like FGF, exists in both the cytoplasm and
the nucleus. The ability of FGF mutants to bind CK2 was
found to correlate with their mitogenic potential. Additional
studies have indicated that intranuclear FGF2 can bind to
the CK2 and can stimulate its activity towards the nucleo-
lar substrate nucleolin [34]. These findings suggest, but
obviously do not prove, a potential function for CK2 in the
intracellular actions of FGF.
These data raise several interesting questions regarding
the intracellular transport and function of FGF: what is the
precise mechanism of FGF exit from the vesicular com-
partment following endocytosis? Is the nuclear localization
of FGF truly of functional significance, or are its intracyto-
plasmic actions more relevant? What happens in
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cell/animal models where CK2 is either knocked down or
knocked out (i.e. one would predict a decrease in FGF
action)? What are the relevant substrates for CK2 in both
the cytoplasm and nucleus? These points are discussed
at length in two recent reviews on the intranuclear function
of FGF [35,36].
Prolactin
PRL has been reported in the nucleus of T cells and
human breast cancer cell lines following co-mitogenic
stimulation [19,37]. The nuclear uptake of PRL appears
to be widespread, as previous biochemical and/or
immunohistochemical studies have demonstrated this
ligand in tissues of the breast, the immune system, the
liver, the ovary, and the adrenal [38–40]. Nuclear retro-
transport occurs within 1–2 hours of extracellular ligand
stimulation and is dependent upon the PRLr. Immunogold
electron microscopy studies using anti-PRL antibodies
and colloidal gold-labeled PRL have revealed that, follow-
ing endocytosis, the ligand is retrotransported from the
endosome into the multivesicular body, where the ligand
is either targeted into the lysosome (presumably for
degradation) or into the Golgi/ER [20]. Shortly after this,
ligand can be noted within the nucleus. When transfected
into T-cell lines neither the secreted wild-type PRL (con-
taining an ER leader sequence) nor a mutant of PRL
lacking its leader (which accumulated in the cytoplasm)
had a significant effect on T-cell growth. However, mutant
PRL containing the SV40 large T nuclear signal
sequence in place of the ER leader induced robust T-cell
proliferation [21].
The mechanisms for PRL nuclear retrotransport and
action were not fully appreciated until followup studies
were performed to identify the binding partners of inter-
nalized PRL capable of mediating such functions. A yeast
two-hybrid analysis was performed with PRL as bait to
identify PRL-binding partners. This analysis, confirmed by
in vitro and in vivo binding studies, revealed that a signifi-
cant binding partner for PRL was the peptidyl prolyl iso-
merase (PPI) cyclophilin B (CypB). A ubiquitously
expressed 22 kDa protein secreted from most cells,
CypB is found in serum and milk, and also within cell
nuclei. Exogenously applied CypB was found to dramati-
cally potentiate PRL and growth hormone-driven prolifera-
tion and to potentiate gene expression (i.e. β-casein or
Spi2.1), but only in cell types expressing either the PRLr
or the GHr [37].
The observation of an interaction between CypB and PRL
has enabled further insights into the mechanisms of PRL
retrotransport and intranuclear function. Following endo-
cytosis, PRL is presumably released from its receptor as a
consequence of vesicular acidification, thus enabling
transport from the multivesicular body to the Golgi/ER.
Retrotransport of many bacterial toxins and MHC-targeted
peptides has been demonstrated to occur via the Sec61
apparatus [41,42]. Of note, the PRL/CypB complex can
also be co-immunoprecipitated with the Sec61 pore
following endocytosis of this complex, an event that paral-
lels the activation of PRLr-affiliated signaling pathways
[19,20]. Nuclear transport of the PRL/CypB complex is
facilitated by a newly recognized nuclear translocation
signal in the N-terminus of CypB [37]. CypB mutants
lacking this signal, while enzymatically active and fully
capable of binding PRL, did not potentiate PRL-driven
proliferation or the intranuclear accumulation of PRL.
Taken together, these findings have revealed that CypB
serves as a ‘reverse’ chaperone, facilitating the transport
of PRL from the vesicular compartment into the nucleus.
Within the nucleus, the PRL/CypB complex has been
found to interact with Stat5 in a PPI-dependent manner
and to potentiate the activity of this transcription factor.
Stat5 is a well-recognized mediator of PRL action within
the mammary gland, as Stat5a knockout mice fail to
lactate [43]. Following tyrosine phosphorylation by recep-
tor-activated Jak2, Stat5 is known to dimerize, to trans-
locate into the nucleus, and to bind to cognate DNA
binding sites. Electrophoretic mobility shift analysis
revealed that the PRL/CypB complex facilitated Stat5
DNA binding, in a manner that indicated the PRL/CypB
complex was removing a repressor of Stat5 function. Co-
immunoprecipitation analysis demonstrated this repressor
to be the peptide inhibitor of activated Stat3 [44]. The
exogenous addition of PRL/CypB released the peptide
inhibitor of activated Stat3 from intranuclear Stat5,
thereby enhancing Stat5 DNA binding [45]. The
PRL/CypB complex directly interacts with the N-terminus
of Stat5 and appears to induce a conformational change
in this transcription factor, enabling the release of peptide
inhibitor of activated Stat3 (PIAS3), thereby facilitating its
association with additional elements of the transcriptional
apparatus with Stat5 [45].
The functions of the PRL/CypB complex are dependent
upon the PPI activity of CypB. While perfectly capable of
binding PRL and undergoing nuclear retrotransport, CypB
mutants deficient in this enzymatic activity are incapable of
stimulating Stat5-mediated gene expression or prolifera-
tion. Indeed, the PPI-deficient CypB mutants are able to
block the proliferation of breast cancer cell lines at con-
centrations two to three orders of magnitude less than
other described mutant PRL antagonists [45].
These studies raise several interesting questions regard-
ing the PRL/CypB complex: how does CypB facilitate the
transport of PRL across the Sec61 pore? What are the
other intranuclear targets of PRL/CypB? How important is
CypB to PRL function in vivo? Answers to these ques-
tions will provide additional details regarding the function
and relevance of this ligand/isomerase complex.
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Conclusions and perspective
The intranuclear transport and function of polypeptide
ligands and their receptors have been a matter of consid-
erable scientific debate over the past decade. Some of
this controversy was due to a lack of mechanistic ground-
ing inherent in the initial descriptions of intranuclear ligand
and/or receptor. As outlined in the present review,
however, the recent demonstration of pathways for the
nuclear translocation of peptide ligands and receptors (i.e.
receptor cleavage, ligand association with binding pro-
teins/chaperones, etc.) from the cell surface/vesicular
compartment and bona fide targets for intranuclear action
(i.e. DNA, transcription factor, or kinase binding) should
lay to rest many of these mechanistic concerns. Indeed,
these studies provide an intelligent basis for speculation
regarding how a ligand/receptor complex may make its
way into the nucleus and exert functional activity at this
site [46].
Acceptance of an intranuclear function for polypeptide
ligands and their receptors, however, is not universal. This
may be due to a lack of a larger perspective on the
intranuclear action of all ligand/receptor complexes. Many
of the concerns regarding the function of intranuclear
polypeptide ligand/receptors can be addressed by exam-
ining the parallels that exist with other acknowledged sig-
naling pathways. For instance, the ability of polypeptide
receptors and, in particular, receptor fragments (such as
the soluble erbB-4 intracytoplasmic domain) to function
within the nucleus as a transcription factor/co-activator is
highly analogous to Notch-associated signaling within the
mammary gland [47]. Indeed, cleavage of the erbB-4 intra-
cytoplasmic domain may use similar, if not identical, pro-
teases required for the cleavage of the transcriptionally
active Notch intracellular domain. Additional mechanistic
parallels can also be drawn between the PRL/CypB
complex and the actions of steroid/steroid receptor com-
plexes (see Fig. 1). While the intranuclear actions of
steroid receptor complexes have long been appreciated,
the function of these complexes at the cell surface has
only been recently recognized [48]. Indeed, the rapid
‘nongenomic’ functions of steroid receptor complexes
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Figure 1
Parallels between prolactin and steroid-induced signal transduction. Classic theory has the prolactin (PRL)/prolactin receptor effecting gene
expression ‘at-a-distance’ through actions of receptor-associated signaling networks, such as the Jak2/Stat5 and Raf/mitogen-activated protein
kinase (MAPK) pathways. A growing body of evidence indicates, however, that following receptor-mediated endocytosis a complex between PRL
and cyclophilin B (CypB) undergoes nuclear retrotranslocation, possibly through the Sec61 pore. Within the nucleus, the PRL/CypB complex
binds to repressed Stat5 complexes, inducing the release of peptide inhibitor of activated Stat3 (PIAS3) enabling Stat5 to engage DNA. In
addition, the PRL/CypB complex interacts with other elements of the transcriptional apparatus (Tfx). Like PRL/CypB, steroid/steroid receptors (GR)
are also able to translocate into the nucleus, where they act as transcription factors. In contrast to these genomic actions of steroid receptors, the
nongenomic actions of steroid/steroid receptor complexes occur at the cell surface, are rapid, and utilize some of the same signaling networks
utilized by the polypeptide ligand/receptor complexes (i.e. MAPK). ER, endoplasmic reticulum.186
appear to utilize many of the signaling pathways associ-
ated with polypeptide receptors.
Many questions remain regarding the transport and
actions of intranuclear polypeptide ligands and receptors.
First, the mechanisms surrounding the extrication of mem-
brane-inserted, full-length receptors need to be estab-
lished. Second, the molecular basis for retrotransport of
ligand into the cytoplasm requires further detailing. Third,
the targets of intranuclear ligands and receptors (i.e.
gene loci, transcription factors, kinases, etc.) are largely
unidentified. Finally, detailing of the larger in vivo context
for the actions of intranuclear ligand/receptor complexes
at the tissue and organismal level will provide a final level
of proof necessary to establish the biologic relevance of
this process.
Several theories currently exist regarding how signaling
specificity is achieved in a given cell by ligand/receptor
complexes that share several common transduction path-
ways [49,50]. While some data support the notion that
rare signaling pathways may be uniquely associated with
a given receptor, most evidence now supports the notion
that a combination of signals emanating from a given
receptor results in signaling specificity. These signals
may be modified in unique ways by the duration of recep-
tor action, by compartmentalization of the receptor or its
associated signaling networks, and by the proteome of a
given cell. However, a rigorous demonstration of how
combinatorial signaling alone works to achieve speci-
ficity in the context of peptide hormones remains to be
demonstrated.
The identification of the intranuclear transport and action
of polypeptide ligands and receptors may therefore
provide an additional key to the conundrum of
hormone/growth factor specificity. As such, the hypothe-
sis emerging from these data would suggest that it is the
function of ligand/receptor complexes in the nucleus that
provides an additional level of direct regulation requisite
for the specificity. Given this, the advances made in our
understanding of the intranuclear actions of polypeptide
ligands and receptors hold considerable pharmacologic
promise. As evinced by the PPI-deficient CypB mutants,
the development of pharmacophores capable of interrupt-
ing the intranuclear transport and/or function of these
polypeptides may provide highly effective agents capable
of inhibiting the hormone/growth factor-driven proliferation
and progression of breast malignancies.
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